# Zabilugene almadenorepvec PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zabilugene-almadenorepvec

> The FDA approved zabilugene almadenorepvec, sponsored by Theriva Biologics, Inc. (TOVX), on Sep 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | zabilugene almadenorepvec |
| Codes | VCN-01 |
| Sponsor | Theriva Biologics, Inc. (TOVX) https://sec-api.dev/companies/tovx/catalysts |
| Indications | [metastatic pancreatic ductal adenocarcinoma](https://sec-api.dev/indications/metastatic-pancreatic-ductal-adenocarcinoma), mpdac for whom gemcitabine/nab-paclitaxel, refractory retinoblastoma conducted, refractory retinoblastoma |
| Modality | gene_therapy |
| FDA designations | fast track, orphan |

## Timeline

### Sep 2022: FDA approval

- Status: completed, approved. Date confidence: month. Stage: 2.
- First seen 2025-03-06, last confirmed 2025-11-12.
- SEC Form 10-Q (accession 0001104659-25-109828): "In September 2022, we received approval from the FDA to proceed with the Phase 2 clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (mPDAC)." https://www.sec.gov/Archives/edgar/data/894158/000110465925109828/tmb-20250930x10q.htm
- SEC Form 10-K (accession 0001410578-25-000285): "In September 2022, the Company received approval from the FDA to proceed with the Phase 2 clinical trial of VCN-01 in PDAC." https://www.sec.gov/Archives/edgar/data/894158/000141057825000285/tmb-20241231x10k.htm

### April 23, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: refractory retinoblastoma.
- First seen 2024-11-12, last confirmed 2026-03-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-021379): "In April 2024, we announced positive topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma conducted at Sant Joan de Déu-Barcelona Children's Hospital." https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_ex99-1.htm
- SEC Form 10-Q (accession 0001410578-24-001850): "On April 23, 2024, we announced positive topline data from the investigator sponsored Phase 1 Trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma." https://www.sec.gov/Archives/edgar/data/894158/000141057824001850/tmb-20240930x10q.htm
- SEC Form 10-K (accession 0001104659-26-026767): "On April 23, 2024, the Company announced positive topline data from this study, with agreement by the study Monitoring Committee that the study had a positive outcome." https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/tmb-20251231x10k.htm
- SEC Form 10-Q (accession 0001410578-25-001242): "On April 23, 2024, we announced positive topline data from this study, with agreement by the study Monitoring Committee that the study had a positive outcome." https://www.sec.gov/Archives/edgar/data/894158/000141057825001242/tmb-20250331x10q.htm
- SEC Form 10-K (accession 0001410578-25-000285): "On April 23, 2024, we announced positive topline data from this study, with agreement by the study Monitoring Committee that the study had a positive outcome." https://www.sec.gov/Archives/edgar/data/894158/000141057825000285/tmb-20241231x10k.htm
- SEC Form 10-Q (accession 0001410578-24-001850): "On April 23, 2024, we announced positive topline data from this study, with agreement by the study Monitoring Committee that the study had a positive outcome." https://www.sec.gov/Archives/edgar/data/894158/000141057824001850/tmb-20240930x10q.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-03-06, last confirmed 2025-03-31.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-029654): "2024 and topline clinical outcomes data are anticipated in Q2 2025." https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/tm2510883d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-029654): "Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to provide topline data in Q2 2025 and generate positive clinical data that establishes" https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/tm2510883d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-021379): ""intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding topline data expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-029654): ""intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding topline clinical outcomes data being anticipated in Q2 2025; the second positive IDMC review of VCN-01 safety data from a larger number of patients affirming the feasibility of repeated VCN-01 dosing in metastatic PDAC patients; and these data, in combination with the previously reported feedback from the FDA and EMA, guiding the design of a potential Phase 3 registrational trial for discussion with regulatory agencies later this year." https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/tm2510883d1_ex99-1.htm

### May 7, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-03-06, last confirmed 2026-03-12.
- SEC Form 10-K (accession 0001104659-26-026767): "On May 7, 2025, we announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating our lead product candidate VCN-01 (zabilugene almadenorepvec) plus SoC chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with mPDAC for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option." https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/tmb-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-109828): "On May 7, 2025, we announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating our lead product candidate VCN-01 (zabilugene almadenorepvec) plus standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with mPDAC for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option." https://www.sec.gov/Archives/edgar/data/894158/000110465925109828/tmb-20250930x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001654): "On May 7, 2025, we announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating our lead product candidate VCN-01 (zabilugene almadenorepvec) plus standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option." https://www.sec.gov/Archives/edgar/data/894158/000141057825001654/tmb-20250630x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001654): "On May 7, 2025, we announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating the Company's lead product candidate VCN-01 (zabilugene almadenorepvec) plus standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option." https://www.sec.gov/Archives/edgar/data/894158/000141057825001654/tmb-20250630x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001242): "On May 7, 2025, we announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating the Company's lead product candidate VCN-01 (zabilugene almadenorepvec) plus standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option." https://www.sec.gov/Archives/edgar/data/894158/000141057825001242/tmb-20250331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-021379): "- Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 -" https://www.sec.gov/Archives/edgar/data/894158/000110465925021379/tm258283d1_ex99-1.htm
- SEC Form 10-Q (accession 0001410578-25-001242): "Topline data for the VIRAGE Phase 2b clinical trial are anticipated for Q2 2025." https://www.sec.gov/Archives/edgar/data/894158/000141057825001242/tmb-20250331x10q.htm
- SEC Form 10-K (accession 0001410578-25-000285): "Topline data for the VIRAGE Phase 2b clinical trial is anticipated for Q2 2025." https://www.sec.gov/Archives/edgar/data/894158/000141057825000285/tmb-20241231x10k.htm

### August 11, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-08-11, last confirmed 2026-08-11.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-093782): "As recently announced, the first patients have been dosed in the VIRAGE2 Phase 2a clinical trial entitled "A" https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_ex99-1.htm

### Q1 2027: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-03-12, last confirmed 2026-08-11.
- SEC Form 10-Q (accession 0001104659-26-093786): "Based on our current plans, we expect that our current cash will be sufficient to fund operations into the first quarter of 2027 and will only be sufficient to cover overhead costs, commence an approved Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period, conduct exploratory VCN-01 manufacturing scale-up activities, complete regulatory interactions regarding a proposed pivotal clinical trial of VCN-01 in retinoblastoma, and undertake limited preclinical studies supporting VCN-01 and VCN-12, the first candidate from our VCN-X discovery program." https://www.sec.gov/Archives/edgar/data/894158/000110465926093786/tmb-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-055689): "Based on our current plans, we expect that our current cash will be sufficient to fund operations into the first quarter of 2027 and will only be sufficient to cover overhead costs, commence a proposed Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period, exploratory VCN-01 manufacturing scale-up activities, regulatory interactions regarding a proposed pivotal clinical trial of VCN-01 in retinoblastoma, and limited preclinical studies supporting VCN-01 and VCN-12, the first candidate from our VCN-X discovery program." https://www.sec.gov/Archives/edgar/data/894158/000110465926055689/tmb-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-026767): "Based on our current plans, we expect that our current cash will be sufficient to fund operations into the first quarter of 2027 and will only be sufficient to cover overhead costs, close out of the VIRAGE Phase 2b clinical trial, commence and complete a potential Phase 2a study evaluating VCN-01 dosing frequency, exploratory VCN-01 manufacturing scale-up activities, regulatory interactions regarding proposed VCN-01 clinical trials in PDAC and retinoblastoma, and preclinical studies supporting VCN-01 and VCN-12, the first candidate from our VCN-X discovery program." https://www.sec.gov/Archives/edgar/data/894158/000110465926026767/tmb-20251231x10k.htm

### Q3 2027: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125912): "- VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 -" https://www.sec.gov/Archives/edgar/data/894158/000110465926125912/tm2629526d1_ex99-1.htm

## Same indication

- [SULANDA® (surufatinib)](https://sec-api.dev/pdufa/surufatinib) (HCM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zabilugene-almadenorepvec.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zabilugene almadenorepvec PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zabilugene-almadenorepvec

```bibtex
@misc{secapidev_pdufa_zabilugene_almadenorepvec_20261116,
  title        = {Zabilugene almadenorepvec PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zabilugene-almadenorepvec}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zabilugene_almadenorepvec_20261116","title":"Zabilugene almadenorepvec PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zabilugene-almadenorepvec","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
